Latest Articles

Publication Date
Expert Opinion: Place in Therapy of Probiotics in Infertility and Recurrent Implantation Failure - Cureus

Expert Opinion: Place in Therapy of Probiotics in Infertility and Recurrent Implantation Failure Cureus

Published: March 24, 2025, 11:52 p.m.
NHS approval of endometriosis therapy Ryeqo enhances patient care: GlobalData - Express Pharma

NHS approval of endometriosis therapy Ryeqo enhances patient care: GlobalData Express Pharma

Published: March 20, 2025, 8:30 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
NHS approval of endometriosis therapy Ryeqo enhances patient care - The Hippocratic Post

NHS approval of endometriosis therapy Ryeqo enhances patient care The Hippocratic Post

Published: March 19, 2025, 12:01 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer 2 Minute Medicine

Published: March 17, 2025, 11:07 p.m.
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer OncLive

Published: March 17, 2025, 9:22 p.m.
Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer - OncLive

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer OncLive

Published: March 6, 2025, 2:32 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!